Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 9 |
| List of Tables | 9 | 1 |
| List of Figures | 10 | 1 |
| Introduction | 11 | 1 |
| Global Markets Direct Report Coverage | 11 | 1 |
| Allergic Asthma Overview | 12 | 1 |
| Therapeutics Development | 13 | 2 |
| Pipeline Products for Allergic Asthma Overview | 13 | 1 |
| Pipeline Products for Allergic Asthma Comparative Analysis | 14 | 1 |
| Allergic Asthma Therapeutics under Development by Companies | 15 | 3 |
| Allergic Asthma Therapeutics under Investigation by Universities/Institutes | 18 | 1 |
| Allergic Asthma Pipeline Products Glance | 19 | 3 |
| Late Stage Products | 19 | 1 |
| Clinical Stage Products | 20 | 1 |
| Early Stage Products | 21 | 1 |
| Allergic Asthma Products under Development by Companies | 22 | 3 |
| Allergic Asthma Products under Investigation by Universities/Institutes | 25 | 1 |
| Allergic Asthma Companies Involved in Therapeutics Development | 26 | 33 |
| ALK-Abello A/S | 26 | 1 |
| Allergopharma GmbH &Co. KG | 27 | 1 |
| Amgen Inc. | 28 | 1 |
| Aquinox Pharmaceuticals Inc. | 29 | 1 |
| ASIT biotech s.a. | 30 | 1 |
| Aslan Pharmaceuticals Pte. Ltd. | 31 | 1 |
| Chiesi Farmaceutici SpA | 32 | 1 |
| Circassia Pharmaceuticals Plc | 33 | 1 |
| CSL Limited | 34 | 1 |
| F. Hoffmann-La Roche Ltd. | 35 | 1 |
| Fountain Biopharma Inc. | 36 | 1 |
| Genentech, Inc. | 37 | 1 |
| GlaxoSmithKline Plc | 38 | 1 |
| Hydra Biosciences, Inc. | 39 | 1 |
| Infinity Pharmaceuticals, Inc. | 40 | 1 |
| KPI Therapeutics, Inc. | 41 | 1 |
| Mabtech Limited | 42 | 1 |
| Marinomed Biotechnologie GmbH | 43 | 1 |
| Mycenax Biotech Inc. | 44 | 1 |
| NeoPharm Co., Ltd. | 45 | 1 |
| Oxagen Limited | 46 | 1 |
| Panacea Biotec Limited | 47 | 1 |
| Paradigm Biopharmaceuticals Limited | 48 | 1 |
| Pharmaxis Limited | 49 | 1 |
| Protectimmun GmbH | 50 | 1 |
| Shire Plc | 51 | 1 |
| Stallergenes Greer plc | 52 | 1 |
| sterna biologicals Gmbh &Co KG | 53 | 1 |
| Swecure AB | 54 | 1 |
| Synermore Biologics Co Ltd | 55 | 1 |
| The International Biotechnology Center (IBC) Generium | 56 | 1 |
| Verona Pharma Plc | 57 | 1 |
| Xencor, Inc. | 58 | 1 |
| Allergic Asthma Therapeutics Assessment | 59 | 12 |
| Assessment by Monotherapy Products | 59 | 1 |
| Assessment by Combination Products | 60 | 1 |
| Assessment by Target | 61 | 3 |
| Assessment by Mechanism of Action | 64 | 3 |
| Assessment by Route of Administration | 67 | 2 |
| Assessment by Molecule Type | 69 | 2 |
| Drug Profiles | 71 | 92 |
| AcTMP-1 Drug Profile | 71 | 1 |
| Allergen for Allergic Asthma and Allergic Rhinitis Drug Profile | 72 | 1 |
| AQX-1125 Drug Profile | 73 | 5 |
| Arabinogalactan Drug Profile | 78 | 1 |
| ASLAN-004 Drug Profile | 79 | 1 |
| ASM-8 Drug Profile | 80 | 2 |
| beta-escin Drug Profile | 82 | 1 |
| CHF-6001 Drug Profile | 83 | 2 |
| CSL-311 Drug Profile | 85 | 1 |
| dalazatide Drug Profile | 86 | 5 |
| Drug to Inhibit PI3 Kinase Delta for Asthma Drug Profile | 91 | 1 |
| duvelisib Drug Profile | 92 | 11 |
| EP-67 Drug Profile | 103 | 1 |
| Epsi-Gam Drug Profile | 104 | 2 |
| FB-825 Drug Profile | 106 | 1 |
| GNR-044 Drug Profile | 107 | 1 |
| GSK-2245035 Drug Profile | 108 | 2 |
| hdm-ASIT Drug Profile | 110 | 1 |
| HX-100 Drug Profile | 111 | 2 |
| Lactococcus lactis G121 Drug Profile | 113 | 1 |
| Leukothera Drug Profile | 114 | 1 |
| OC-000459 Drug Profile | 115 | 2 |
| OC-2417 Drug Profile | 117 | 1 |
| omalizumab biosimilar Drug Profile | 118 | 1 |
| omalizumab biosimilar Drug Profile | 119 | 1 |
| omalizumab biosimilar Drug Profile | 120 | 1 |
| omalizumab biosimilar Drug Profile | 121 | 1 |
| omalizumab biosimilar Drug Profile | 122 | 1 |
| OND-86 Drug Profile | 123 | 1 |
| pemirolast potassium Drug Profile | 124 | 1 |
| pentosan polysulfate sodium Drug Profile | 125 | 1 |
| RG-6149 Drug Profile | 126 | 1 |
| RG-7990 Drug Profile | 127 | 1 |
| RPL-554 Drug Profile | 128 | 8 |
| SB-010 Drug Profile | 136 | 2 |
| SG-100 Drug Profile | 138 | 2 |
| SM-301 Drug Profile | 140 | 1 |
| Small Molecule for Allergic Asthma Drug Profile | 141 | 1 |
| Small Molecules for Allergic Asthma Drug Profile | 142 | 1 |
| Small Molecules to Inhibit 5-Lipoxygenase for Allergic Asthma Drug Profile | 143 | 1 |
| Small Molecules to Inhibit CaMKII for Allergic Asthma Drug Profile | 144 | 1 |
| standardized grass pollen [timothy (Phleum pratense)] allergen extract Drug Profile | 145 | 3 |
| standardized mite (Dermatophagoides farinae + Dermatophagoides pteronyssinus) allergen extract Drug Profile | 148 | 2 |
| standardized mite (Dermatophagoides pteronyssinus + Dermatophagoides farinae) allergen vaccine Drug Profile | 150 | 5 |
| SWE-01 Drug Profile | 155 | 1 |
| Synthetic Peptides for Allergic Asthma and Rheumatoid Arthritis Drug Profile | 156 | 1 |
| tezepelumab Drug Profile | 157 | 2 |
| Vaccine for Allergic Asthma Drug Profile | 159 | 1 |
| Vaccine for Grass-Induced Rhinoconjunctivitis and Asthma Drug Profile | 160 | 2 |
| XmAb-7195 Drug Profile | 162 | 1 |
| Allergic Asthma Dormant Projects | 163 | 4 |
| Allergic Asthma Discontinued Products | 167 | 1 |
| Allergic Asthma Product Development Milestones | 168 | 12 |
| Featured News &Press Releases | 168 | 1 |
| Jul 27, 2016: ASLAN Pharmaceuticals Enters Service Agreement with Selexis SA for Development of a Proprietary Cell Line for Expression of ASLAN004 | 168 | 1 |
| May 16, 2016: Sorrento Announces Positive Data from a Combined Phase 2 &3 Clinical Study of STI-004, an Anti-IgE Biosimilar Antibody | 168 | 1 |
| Apr 27, 2016: Journal of the American Medical Association publishes Phase III data from allergic asthma trial with ALK house dust mite SLIT-tablet, ACARIZAX | 169 | 1 |
| Jan 14, 2016: ALK announces top-line results from the five-year landmark GRAZAX Asthma Prevention trial in children | 170 | 1 |
| Jan 06, 2016: Hydra Biosciences to Present at the 8th Annual Biotech Showcase Conference in San Francisco on Jan. 11 | 171 | 1 |
| Aug 31, 2015: ALK obtains European approval for its house dust mite sublingual allergy immunotherapy tablet against allergic rhinitis and allergic asthma | 171 | 1 |
| Jun 26, 2015: Xencor Provides Update on XmAb-7195 And Expansion of Bispecific Oncology Pipeline at R&D Day | 172 | 1 |
| May 22, 2015: Successful testing of new drug for allergic asthma | 173 | 1 |
| May 18, 2015: Fraunhofer ITEM: Successful Testing of New Drug for Allergic Asthma | 174 | 1 |
| Apr 14, 2015: Hydra Biosciences Receives Approval from Health Canada to Begin Phase 1 Trial for HX-100 | 175 | 1 |
| Jul 11, 2013: Positive results from pivotal Phase III trial of new allergy immunotherapy tablet against house dust mite-induced allergic asthma | 176 | 1 |
| Apr 08, 2013: S-Target Achieves In Vivo Proof Of Concept For Its Allergy Vaccine SG100 | 177 | 1 |
| Mar 27, 2013: Merck Announces FDA Acceptance Of Biologics License Application For Investigational Grass Pollen Allergy Immunotherapy Tablet | 178 | 1 |
| Apr 17, 2012: Pharmaxis Completes Phase II Clinical Study With ASM8 In Asthma Patients | 178 | 2 |
| Appendix | 180 | 2 |
| Methodology | 180 | 1 |
| Coverage | 180 | 1 |
| Secondary Research | 180 | 1 |
| Primary Research | 180 | 1 |
| Expert Panel Validation | 180 | 1 |
| Contact Us | 180 | 1 |
| Disclaimer | 181 | 1 |